Abeona Therapeutics’ (ABEO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report released on Friday, Benzinga reports. The firm currently has a $18.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on ABEO. HC Wainwright restated a buy rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday, August 14th. StockNews.com upgraded Abeona Therapeutics from a sell rating to a hold rating in a report on Tuesday, September 10th. Finally, Stifel Nicolaus assumed coverage on shares of Abeona Therapeutics in a report on Thursday, May 30th. They issued a buy rating and a $21.00 price objective for the company.

Abeona Therapeutics Stock Up 3.8 %

Shares of NASDAQ ABEO opened at $6.02 on Friday. The company has a market cap of $246.60 million, a price-to-earnings ratio of -1.88 and a beta of 1.53. The company has a current ratio of 7.48, a quick ratio of 7.48 and a debt-to-equity ratio of 0.22. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The stock has a 50-day moving average price of $5.23 and a two-hundred day moving average price of $5.46.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.42). As a group, analysts forecast that Abeona Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rosalind Advisors Inc. acquired a new position in shares of Abeona Therapeutics in the second quarter worth approximately $7,420,000. Western Standard LLC increased its position in Abeona Therapeutics by 68.5% during the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock valued at $9,871,000 after purchasing an additional 553,377 shares during the period. Renaissance Technologies LLC lifted its position in shares of Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Abeona Therapeutics in the 2nd quarter worth approximately $1,732,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Abeona Therapeutics by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 2,434 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.